A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data, we compare the effectiveness of these IL-6 i...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Maaike C. Swets, Rob J. Moss, Flip Kor, Doranne Hilarius, Dirk Jan A.R. Moes, Willemijn EM Berkhout, Leon M. van den Toorn, Niels C. Gritters van den Oever, Renee de Valk, Frits R. Rosendaal, Nicole Hunfeld, Geert H. Groeneveld, Mark G.J. de Boer
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2023-04-01
Σειρά:	International Journal of Infectious Diseases
Θέματα:	IL-6 inhibitor COVID-19 SARS-CoV-2 Tocilizumab Sarilumab
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S1201971223000413
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!